Primary AldosteronismNCT07182175
Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors
An observational study of Primary Aldosteronism and Adrenal Tumor, run by Peking University First Hospital at 1 site in China.
Trial summary
The main goal of this study is to follow patients with functional adrenal tumors during the time before and after their surgery. The main questions it aims to answer are: What heart and blood pressure changes do patients with different types of adrenal tumors have before surgery? What factors affect how the heart and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Primary Aldosteronism, Adrenal Tumor, Cushing s Syndrome
- How many people
- 150 participants
- Where
- 1 siteChina
- Study dates
- 19 Sep 2024to 29 May 2026
- How long will I take part?
- 48 Weeks
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of patients with functional adrenal tumors who are hospitalized and/or seen in the outpatient clinic of the Department of Urology at Peking University First Hospital.
Who may be able to join
- Patients diagnosed in the Department of Urology, Peking University First Hospital with pheochromocytoma and paraganglioma (PPGL), primary aldosteronism (PA), or Cushing syndrome (CS);
- Written informed consent obtained.
Who cannot join
- Patients with PPGL, PA, or CS who receive medication or conservative treatment and are not eligible for surgical resection;
- Patients with communication disorders or severe physical impairments such as aphasia, or visual/hearing disabilities;
- Patients with severe mental illness who cannot cooperate with the study;
- Pregnant women or patients otherwise deemed unsuitable for participation by the investigators.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Dynamic Monitoring and Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors
The main goal of this study is to follow patients with functional adrenal tumors during the time before and after their surgery.
The main questions it aims to answer are:
Read more
- What heart and blood pressure changes do patients with different types of adrenal tumors have before surgery?
- What factors affect how the heart and blood pressure recover after surgery?
- Do the heart and blood pressure conditions before surgery influence recovery and the risk of heart or brain problems after surgery?
Patients will have heart ultrasound checks and health monitoring before and after surgery. The results will help doctors choose the right medicines before surgery, better understand possible risks during the operation, and make safer treatment plans for patients with functional adrenal tumors.
- Conditions
- Primary Aldosteronism, Adrenal Tumor, Cushing s Syndrome, Pheochromocytoma/Paraganglioma (PPGL)
- Medical subject headings
- Hyperaldosteronism, Adrenal Gland Neoplasms, Pheochromocytoma, Paraganglioma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| primary aldosteronism | Not described | |
| Cushing s Syndrome | Not described | |
| Pheochromocytoma/Paraganglioma (PPGL) | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recovery of cardiac function after adrenal surgery
global longitudinal stress
Measured: from enrollment to 4,24,48 weeks after surgery
Secondary outcomes (1)
Recovery of blood pressure after adrenal surgery
Decrease in 24h average blood pressure
Measured: from enrollment to 4,24,48 weeks after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2025
- Study start19 Sep 2024
- Primary completion17 Nov 2024
- Study completion29 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Primary AldosteronismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
- Target duration
- 48 Weeks
Sponsor and investigators
- Lead sponsor
- Peking University First Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07182175
- Sponsor's protocol ID
- 2024yan411-002
- Status last verified
- Sep 2025
- First submitted
- 11 Sep 2025
- Last updated
- 19 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data cannot be shared, because data from this study may contain potentially or sensitive patient information.